Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scratch my head here lol..
SRNEQ: And, this little (Bankupt??) puppy just keeps creeping-up BARCHART's glorious global list --- despite these crappy markets of late.
https://www.barchart.com/investing-ideas/penny-stocks?orderBy=percentChange5d&orderDir=desc
That's for sure. I bailed out Tuesday to break even and got back in at .21 yesterday. GLTUA
SRNEQ: EXTREME volatility everywhere these days; but, I still think SRNEQ is a classic 'sleeper' play. E.g., don't think this will languish in Bankruptcy Court for very long.
i should have gotten….
….
back in at 17’s yesterday but congrats to those that bought low then.
SRNEQ: Easy money here today, Peeps! Where is everybody??? (Gettin' SUCKERED by 'CANCER-CURE-MORNING-GAPPERS' of the day???)
WHAT ARE SCILEX AND SORRENTO NEAR TERM SHARE PRICE MOVERS?
I'm glad to have some SCILEX shares because SEMDEXA, ZTlido, Gloperba (gout), EYYXYB (migraine) and SP-103 (lower back pain) all look like winners to me. And the sales force is already in place! And world-wide partnerships are coming!
But my main interest is in SORRENTO! They hold a majority interest in SCILEX so will benefit from SCILEX's success! But they also have ABIVERTINIB and SOCAZOLIMAB which look to be approved in the big Chinese market this year. They also have a potential multi-blockbuster in the oral anti-viral OVYDSO which China moved from a phase 1b trial directly into a pivotal phase 3 trial! This trial is obviously fast-tracked as the first phase 3 patient was dosed Feb.7! And might China also be interested in Sorrento's second generation mRNA vaccine? These also are all partnerable! And I must admit I would not be surprised to hear some good news about the SOFUSA, RTX, VIREX and DAR-T programs! And I like Sorrento's chances in the upcoming PSS trial!
There is a lot of news coming in 2023. Much of it in the next few months IMO.I don't know of another small biotech with so many potential blockbusters!
rearrange the deck chairs.
Here is more information on the trial in China. First patient was dosed Feb.2 2023 and the trial will be completed in a few months! Ignore the completion dates...1200 patients in 40 hospitals will recruit rapidly!
https://www.clinicaltrials.gov/ct2/show/NCT05716425
OVYDSO (oral anti-viral) phase 3 trial began dosing in China Feb.2 2003! Summary...
"40 trial centers with an avg. 30 patients per center. Trial is double blinded, 50/50 Mpro v. placebo, 600 patients get Mpro and 600 get a placebo. Dosing 2x day for 5 days + 24 days follow up (+29Days from day 1). Trial could be completed rapidly ..." Pfizer drug(with liver and drug/drug interaction problems) with very high cost(subsidized by Western governments) earned $20+ Billion last year!
yup, but just watching for now.
We may have just hit bottom at .17. It may be time for a run back up.
just watching for now.
Set that buy order at .02 for tomorrow.
good choice! it may be a….
….
good time to buy now though.
Appear I chose stay on side is a right choice Gail! No headache trading):
Stock loses 90% of its value, a CEO that can’t get a Covid test approved, nothing to market, wait a $40 billion dollar pipeline…no, nobody is bitter. Wait until the lawsuits start, now delisted, it’s done. The great Dr. Scam is done.
EKDKQ ….. have a great evening and gl …
Nice repot Renee, and for Gail it was a good thing she got out before the dump. All these so called experts, who seem to know everything, trust me right now they are getting there asses handed to them. Some wise investors right now are saying they may wash there hands and wait out this Recession, That is very good advise, its ugly out there folks.
SRNE changed to SRNEQ, bankruptcy. Delisted from the Nasdaq to the OTC, effective Feb. 23,2023.
https://otce.finra.org/otce/dailyList?viewType=Additions
Every fool that bought this at 10.00+ when insiders were selling shares and spreading covid China. Been posting here fir years about 250 mil loss in the 8k 2 years ago. Stock market is fir the smart to steal from the Stupid. Hence SRNE
Lol people got jokes only when it drops
Agree I keep loading these cheapies
It's not a dump. It's a pullback. Pullbacks are healthy. We're closing much higher by EOW.
glad i got out before the dump. it was worth a try.
it was looking good until they yanked it right back down in a/h.
It'll turn around and head back up. Just closing the gap for now.
Bankruptcy Court Approval Causes Premarket Buying Pressure
Source: AllPennyStocks.com
A California-based biotech company is turning heads Wednesday morning after it was announced that the U.S. Bankruptcy Court granted an interim approval of the company’s $75...
To read the full story on AllPennyStocks.com, click here.
Trying to hard to keep it down let’s burn them hard $$$$
SRNE: YEP!! Let's do it!!
75 million is alot of Money for a company fighting a naked short suppression. Any announcement could send this flying.
Can you flesh that theory out a bit?
Oh yeah. They slapped their short positions hard after the BK announcement. Will see how hard this squeezes. Has traded over 100 million in volume on multiple days.
4-7x on massive afterhours news.
May see this run over $2.00 on that 75 mill financing.
I’m guessing we see some big moves and fast from SRNE now!!
.52 . while most were sleeping hit 43
Chicken never make money...I consider myself! Dammm saw .30 afraid buy....saw .40 today stay away ..now .50+ watching rising
Need to keep NASDAQ listing. That would be nice
great news for them. no wonder its been inching up, i had a feeling something good was coming.
Hit .61 AH. You were close.
Followers
|
282
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
14952
|
Created
|
03/09/07
|
Type
|
Free
|
Moderators |
While being laser-focused on just one objective can have its advantages, having a wider-based remit can be just as effective, if done well.
That is certainly the opinion of Alliance Global analyst James Molloy when evaluating Sorrento’s prospects.
So, what’s on offer from the Sorrento menu in the near-term?
The company has already filed an EUA for COVI-STIX, a 15-minute nasal swab antigen test for SARS-CoV-2, in the US and Mexico, and the test could be launched as early as 1H21.
Accurate COVID tests are still needed in the US and around the globe, and Molloy expects the assay to gain EUA approval and could “rapidly approach $500M in sales as soon as 2022.“
SRNE's 8-minute SARS-CoV-2 antibody test COVID-TRACK could swiftly follow in its footsteps with an EUA anticipated to be filed in the year’s first half, too. “This could easily be another $500million+ near term opportunity,” Molloy said.
Furthermore, the company’s two neutralizing antibody treatments, COVI-DROPS and COVI-AMG, against SARS-CoV-2, could be launched in 2022. Each of these, as well, have the potential to bring in more than $500 million in sales, according to the analyst
The company’s non-opioid pain pipeline also has several late-stage catalysts.
Fast tracked by the FDA, Phase 3 data for sciatica pain candidate SP-102 should be available this year, while RTX for OsteoArthritis (OA) knee pain and intractable cancer pain will kick-off Phase 2 and Phase 3 studies, respectively, in 2021. Both target “substantial market opportunities.”
Last but not least is Abivertinib, the company's oncology lead candidate, indicated for non-small-cell lung cancer (NSCLC) and B-cell lymphomas, and currently in Phase 3 trials in China with top line data anticipated in 1H21.
To this end, based on the progress of the company's pipeline, Molloy sees significant gains in SRNE's future. The analyst rates the stock a Buy and his $35 price target implies a hefty 277% upside. (To watch Molloy’s track record, click here)
Overall, Sorrento currently has few, yet very positive analysts tracking its progress. With Buy ratings only – 3, in total - the stock has a Strong Buy consensus rating. There’s plenty of upside projected, too; At $28.67, the average price target suggests gains of ~209% over the next 12 months. (See SRNE stock analysis on TipRanks)
4955 Directors Place
San Diego, CA 92121
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™, Gene-MAb™, COVI-MSC™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit?www.sorrentotherapeutics.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |